PLANNING TOOLS & RESOURCES

Resources & Reports

Pandemic Planning Update II A Report from Secretary Michael O. Leavitt. June 29, 2006. Department of Health and Human Services. Download this PDF English - 3.4MB

A Potential Influenza Pandemic: An Update on Possible Macroeconomic Effects and Policy Issues. May 22, 2006; revised July 27, 2006 Congressional Budget Office. Download this PDF English - 144KB

Nonpharmaceutical Interventions for Pandemic Influenza, National & Community Measures World Health Organization Writing Group. Download this PDF English - 40KB

Influenza Pandemic—Phases and Strategic Actions Download this PDF English - 768KB

Seasonal Flu vs Pandemic Flu Definition Download this PDF English - 24KB

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA